

REMARKS

The present invention is directed to a new class of androgen modulators. Claims 1-4, 6, 9, and 13-23 were rejected under the first paragraph of 35 USC 112 due to the term "solvate". The undersigned asserts the application does provide enablement for such compounds and reserves the right to pursue such subject matter in a continuation. To expedite prosecution, the claims have been amended to delete this term.


An Information Disclosure Statement was submitted on August 5, 2008, along with the required fee. The undersigned request that the USPTO consider this information when reviewing this submission,

It is respectfully submitted that the claims are in condition for allowance. Withdrawal of the rejection and reconsideration is requested. If any minor amendments are required to place the case in condition for allowance, the undersigned invites a phone call to discuss such amendments.

Date:

8/26/08

Respectfully submitted,


J. Michael Dixon
Attorney for the Applicants
Reg. No. 32,410

Pfizer Inc.
Patent Department
MS8260-1611
Eastern Point Road
Groton, CT 06340
(860) 686-9018